Your browser doesn't support javascript.
loading
What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? A harmonised, global longitudinal observational study protocol.
Sigfrid, Louise; Cevik, Muge; Jesudason, Edwin; Lim, Wei Shen; Rello, Jordi; Amuasi, John; Bozza, Fernando; Palmieri, Carlo; Munblit, Daniel; Holter, Jan Cato; Kildal, Anders Benjamin; Reyes, Luis Felipe; Russell, Clark D; Ho, Antonia; Turtle, Lance; Drake, Thomas M; Beltrame, Anna; Hann, Katrina; Bangura, Ibrahim Richard; Fowler, Robert; Lakoh, Sulaiman; Berry, Colin; Lowe, David J; McPeake, Joanne; Hashmi, Madiha; Dyrhol-Riise, Anne Margarita; Donohue, Chloe; Plotkin, Daniel; Hardwick, Hayley; Elkheir, Natalie; Lone, Nazir I; Docherty, Annemarie; Harrison, Ewen; Baille, J Kenneth; Carson, Gail; Semple, Malcolm G; Scott, Janet T.
Affiliation
  • Sigfrid L; ISARIC Global Support Centre, Centre for Tropical Medicine and Global Heatlh, University of Oxford, Oxford, UK louise.sigfrid@gmail.com.
  • Cevik M; Infection and Global Health Division, School of Medicine, University of St Andrews, St Andrews, UK.
  • Jesudason E; Department of Rehabilitation Medicine, NHS Lothian, Edinburgh, UK.
  • Lim WS; Department of Respiratory Medicine, Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Rello J; Centro de Investigación Biomédica en Red - Enfermedades Respiratorias (CIBERES), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Amuasi J; Research Department, CHU Nîmes, Université Nîmes-Montpellier, Nîmes, France.
  • Bozza F; School of Public Health, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
  • Palmieri C; Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
  • Munblit D; Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
  • Holter JC; Clatterbridge Cancer Centre NHS Foundation Trust, Livepool, UK.
  • Kildal AB; Department of Paediatrics, I M Sechenov First Moscow State Medical University, Moskva, Russia.
  • Reyes LF; IInflammation, Repair and Development Section, National Heart and Lung Institute, Imperial College London Faculty of Medicine, London, UK.
  • Russell CD; Department of Microbiology, Oslo University Hospital, Oslo, Norway.
  • Ho A; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Turtle L; Department of Anesthesiology and Intensive Care, University Hospital of North Norway, Tromso, Norway.
  • Drake TM; Universidad de La Sabana, Chia, Colombia.
  • Beltrame A; The University of Edinburgh Centre for Inflammation Research, Edinburgh, UK.
  • Hann K; University of Glasgow, Glasgow, UK.
  • Bangura IR; NIHR Health Protection Research Unit in Emerging and Zoonotic infections, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.
  • Fowler R; Tropical and Infectious Disease Unit, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
  • Lakoh S; Centre for Medical Informatics, The University of Edinburgh, Edinburgh, UK.
  • Berry C; Department of Infectious Diseases, Tropical and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Italy.
  • Lowe DJ; Sustainable Health Systems, Freetown, Sierra Leone.
  • McPeake J; Dorothy Springer Trust, Freetown, Sierra Leone.
  • Hashmi M; Sunnybrook Health Sciences Institute, Sunnybrook Research Institute, Toronto, Ontario, Canada.
  • Dyrhol-Riise AM; Sustainable Health Systems, Freetown, Sierra Leone.
  • Donohue C; Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
  • Plotkin D; Emergency Department, Queen Elizabeth University Hospital, Glasgow, UK.
  • Hardwick H; NHS Greater Glasgow and Clyde, Glasgow, UK.
  • Elkheir N; Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
  • Lone NI; Department of Critical Care Medicine, Ziauddin University, Karachi, Pakistan.
  • Docherty A; Department of Infectious Diseases, Institute of Clinical Medicine, Oslo University Hospital, Oslo, Norway.
  • Harrison E; National Institute of Health Research (NIHR) Health Protection research Unit in Emerging and Zoonotic Infections, University of Liverpool, Liverpool, UK.
  • Baille JK; Institute of Infection and Global Health, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK.
  • Carson G; Nuffield Department of Medicine, ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.
  • Semple MG; National Institute of Health Research (NIHR) Health Protection research Unit in Emerging and Zoonotic Infections, University of Liverpool, Liverpool, UK.
  • Scott JT; Institute of Infection and Global Health, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK.
BMJ Open ; 11(3): e043887, 2021 03 10.
Article in En | MEDLINE | ID: mdl-33692181
INTRODUCTION: Very little is known about possible clinical sequelae that may persist after resolution of acute COVID-19. A recent longitudinal cohort from Italy including 143 patients followed up after hospitalisation with COVID-19 reported that 87% had at least one ongoing symptom at 60-day follow-up. Early indications suggest that patients with COVID-19 may need even more psychological support than typical intensive care unit patients. The assessment of risk factors for longer term consequences requires a longitudinal study linked to data on pre-existing conditions and care received during the acute phase of illness. The primary aim of this study is to characterise physical and psychosocial sequelae in patients post-COVID-19 hospital discharge. METHODS AND ANALYSIS: This is an international open-access prospective, observational multisite study. This protocol is linked with the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) and the WHO's Clinical Characterisation Protocol, which includes patients with suspected or confirmed COVID-19 during hospitalisation. This protocol will follow-up a subset of patients with confirmed COVID-19 using standardised surveys to measure longer term physical and psychosocial sequelae. The data will be linked with the acute phase data. Statistical analyses will be undertaken to characterise groups most likely to be affected by sequelae of COVID-19. The open-access follow-up survey can be used as a data collection tool by other follow-up studies, to facilitate data harmonisation and to identify subsets of patients for further in-depth follow-up. The outcomes of this study will inform strategies to prevent long-term consequences; inform clinical management, interventional studies, rehabilitation and public health management to reduce overall morbidity; and improve long-term outcomes of COVID-19. ETHICS AND DISSEMINATION: The protocol and survey are open access to enable low-resourced sites to join the study to facilitate global standardised, longitudinal data collection. Ethical approval has been given by sites in Colombia, Ghana, Italy, Norway, Russia, the UK and South Africa. New sites are welcome to join this collaborative study at any time. Sites interested in adopting the protocol as it is or in an adapted version are responsible for ensuring that local sponsorship and ethical approvals in place as appropriate. The tools are available on the ISARIC website (www.isaric.org). PROTOCOL REGISTRATION NUMBER: osf.io/c5rw3/ PROTOCOL VERSION: 3 August 2020 EUROQOL ID: 37035.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Type of study: Clinical_trials / Diagnostic_studies / Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Aspects: Ethics Limits: Humans Country/Region as subject: Africa / America do sul / Asia / Colombia / Europa Language: En Journal: BMJ Open Year: 2021 Document type: Article Country of publication: Reino Unido

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Type of study: Clinical_trials / Diagnostic_studies / Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Aspects: Ethics Limits: Humans Country/Region as subject: Africa / America do sul / Asia / Colombia / Europa Language: En Journal: BMJ Open Year: 2021 Document type: Article Country of publication: Reino Unido